Anaphylaxis Market Report 2026

The anaphylaxis market size has grown strongly in recent years. It will grow from $3.5 billion in 2025 to $3.79 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to rising incidence of food and drug allergies, increased diagnosis of allergic conditions, availability of emergency epinephrine treatments, growing public health awareness, adoption of standardized treatment guidelines.

The anaphylaxis market size is expected to see strong growth in the next few years. It will grow to $5.14 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to increasing access to emergency allergy care, rising demand for portable treatment solutions, expansion of allergy specialty services, growing focus on patient education programs, increasing investment in allergy management infrastructure. Major trends in the forecast period include increasing availability of epinephrine auto-injectors, rising awareness of severe allergic reactions, growing emphasis on emergency preparedness, expansion of allergy diagnosis and monitoring, enhanced focus on rapid response protocols.

The rising prevalence of food allergies is expected to drive the growth of the anaphylaxis market in the coming years. Food allergies are immune system responses triggered by certain foods, causing symptoms that range from mild to severe, including life-threatening anaphylaxis. Factors such as changing dietary habits, environmental influences, and improved awareness and diagnosis are contributing to the increasing prevalence of food allergies. Anaphylaxis treatment provides critical, life-saving intervention for individuals with food allergies by rapidly reversing severe allergic reactions, alleviating symptoms such as swelling, difficulty breathing, and drops in blood pressure, ensuring immediate stabilization, and preventing potentially fatal outcomes. It also equips patients with tools for timely action in future allergic incidents. For example, in September 2024, the World Health Organization (WHO), a Switzerland-based United Nations organization, reported that around 220 million people worldwide are affected by food allergies. A single food product can contain multiple allergens, and individuals may be allergic to more than one type of food. Additionally, in May 2024, the Patterns and Prevalence of Adult Food Allergy (PAFA) report by the Food Standards Agency (FSA), a UK-based non-ministerial department, found that over 30% of adults reported food-related adverse reactions, with clinical assessments confirming food allergies in approximately 6% of UK adults, equating to about 2.4 million people. Consequently, the rising prevalence of food allergies is propelling the growth of the anaphylaxis market.

Key companies in the anaphylaxis market are focusing on developing advanced epinephrine nasal sprays to enable faster and more efficient drug delivery during emergencies. Epinephrine nasal spray is a medical device that delivers epinephrine (adrenaline) through the nasal passages to treat severe allergic reactions, including anaphylaxis. For instance, in August 2024, ARS Pharmaceuticals, a US-based biotechnology company, announced FDA approval for Neffy, an epinephrine nasal spray, marking it as the first and only needle-free treatment for type I allergic reactions, including anaphylaxis. This innovative nasal spray provides a non-invasive alternative to traditional epinephrine autoinjectors, offering a potentially more accessible emergency treatment option. Neffy aims to improve patient compliance by eliminating the need for needles while delivering rapid, life-saving epinephrine during severe allergic reactions.

In October 2023, Nestlé Health Science SA, a Switzerland-based nutritional science company offering anaphylaxis solutions, partnered with Anaphylaxis UK to support individuals with severe allergies. This collaboration seeks to raise awareness about the serious consequences of anaphylaxis and empower people to manage allergies safely through education and resources. Anaphylaxis UK is a UK-based charity dedicated to supporting individuals with severe allergies.

Major companies operating in the anaphylaxis market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi SA, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline Plc, F. Hoffman-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Perrigo Company plc, Dr Reddy’s Laboratories Ltd., Cipla Ltd., Amneal Pharmaceuticals Inc., Mylan N.V., ALK-Abelló, Stallergenes Greer, Allergy Therapeutics.

North America was the largest region in the anaphylaxis market in 2025. The regions covered in the anaphylaxis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anaphylaxis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the anaphylaxis market by increasing costs of imported epinephrine formulations, auto-injector components, syringes, and pharmaceutical packaging materials. Healthcare systems in North America and Europe are most affected due to dependence on imported medical devices and drug components. These tariffs are contributing to higher treatment costs and constrained accessibility for patients. However, they are also promoting domestic production of auto-injectors, localized drug manufacturing, and strengthened regional supply chains for life-saving allergy treatments.

The anaphylaxis market research report is one of a series of new reports that provides anaphylaxis market statistics, including anaphylaxis industry global market size, regional shares, competitors with a anaphylaxis market share, detailed anaphylaxis market segments, market trends and opportunities, and any further data you may need to thrive in the anaphylaxis industry. This anaphylaxis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anaphylaxis is a severe, life-threatening allergic reaction that develops rapidly, often causing difficulty breathing, swelling, and a drop in blood pressure, and requires immediate medical intervention. Management of anaphylaxis involves the prompt administration of epinephrine, followed by careful monitoring in a healthcare setting to stabilize the patient and prevent further complications.

The primary drug classes used in anaphylaxis include epinephrine, steroids, antihistamines, beta-antagonists, and others. Epinephrine is a life-saving medication that rapidly reverses severe allergic reactions by constricting blood vessels, relaxing airway muscles, and increasing heart rate. These medications are administered via routes such as parenteral and oral and are applied in the management of conditions including food allergies, pollen allergies, dust mite allergies, and others.

The anaphylaxis market consists of syringes and vials, intravenous (IV) epinephrine, diagnostic kits, and monitoring devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.